Energy News / Shareholders Foundation, Inc.

NASDAQ: DBVT Shareholder Notice: Lawsuit Against DBV Technologies S.A. Alleges Misleading Statements

Via: ReleaseWire

Updated 11:00 AM CST, Mon, February 04,2019

A lawsuit was filed on behalf of investors in DBV Technologies S.A. (NASDAQ: DBVT) shares over alleged securities laws violations.

San Diego, CA -- (SBWIRE) -- 02/04/2019 -- An investor, who purchased shares of DBV Technologies S.A. (NASDAQ: DBVT), filed a lawsuit over alleged violations of Federal Securities Laws by DBV Technologies S.A.

Investors in shares of DBV Technologies S.A. (NASDAQ: DBVT) have certain options and for certain investors are short and strict deadlines running. Deadline: March 18, 2019. NASDAQ: DBVT investors should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

France based DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. On December 19, 2018, after the US markets closed, DBV Technologies S.A. (NASDAQ: DBVT) made known that following discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut in children four to 11 years of age has been voluntarily withdrawn. The Company stated, "Although the agency did not reference any medical or clinical questions with the submission of Viaskin Peanut, the FDA did communicate that the level of detail with regards to data on manufacturing and quality controls was insufficient in the BLA."

The plaintiff claims that between February 14, 2018 and December 19, 2018, the defendants made false and/or misleading statements and/or failed to disclose that DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls, that consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut, and that as a result, defendants' statements about DBV Technologies' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of DBV Technologies S.A. (NASDAQ: DBVT) have certain options and should contact the Shareholders Foundation.

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

For more information on this press release visit:

Media Relations Contact
Michael Daniels
Email: Click to Email Michael Daniels